Synthesis and pharmacological evaluation of novel arylpiperazine oxicams derivatives as potent analgesics without ulcerogenicity

Bioorg Med Chem. 2019 Apr 15;27(8):1619-1628. doi: 10.1016/j.bmc.2019.03.007. Epub 2019 Mar 2.

Abstract

Gastrotoxicity continues to be a major issue in therapy with nonsteroidal anti-inflammatory drugs (NSAIDs). Medicine is yet to develop absolutely safe analgesics. Numerous strategies are employed to discover new, safer NSAIDs, for example selective inhibition of cyclooxygenase-2, new molecular targets (e.g. microsomal prostaglandin E2 synthase-1), incorporation of cytoprotective compounds in the drug molecule or modification of the classic NSAIDs currently available on the market. The research presented in this paper is indicative of a current worldwide trend in this area of science, and is an example of the fourth strategy noted above. Two series of new arylpiperazine derivatives of the classic NSAID - piroxicam, were developed by conventional synthesis. The full range of compounds obtained proved to be between two and five times analgesically more potent than the reference drug and, most importantly, they did not show any ulcerogenic activity.

Keywords: 1,2-Benzothiazine; Analgesic activity; Oxicams; Synthesis; Ulcerogenicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Analgesics / adverse effects
  • Analgesics / chemistry*
  • Analgesics / pharmacology*
  • Animals
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / chemistry*
  • Anti-Inflammatory Agents, Non-Steroidal / pharmacology*
  • Male
  • Mice
  • Models, Molecular
  • Piperazines / adverse effects
  • Piperazines / chemistry*
  • Piperazines / pharmacology*
  • Piroxicam / adverse effects
  • Piroxicam / analogs & derivatives
  • Piroxicam / pharmacology
  • Rats, Wistar
  • Ulcer / chemically induced

Substances

  • Analgesics
  • Anti-Inflammatory Agents, Non-Steroidal
  • Piperazines
  • Piroxicam